Systemic Therapy for HCC: A Rapidly Evolving Landscape
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Screening for Early Stage HCC By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD A brief overview of criteria and tools used to assess, and risk stratify patients with early stage hepatocellular carcinoma.
EP. 2: Diagnostic Testing for Early Stage HCC By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD The rationale for diagnostic imaging to evaluate and diagnose early stage hepatocellular carcinoma.
EP. 3: Diagnosing Early-Stage HCC via Biopsy By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD A debate regarding the current role of biopsy to confirm a diagnosis of early-stage hepatocellular carcinoma.
EP. 4: Current Role of Locoregional Therapy for Early Stage HCC By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD Edward Kim, MD, of Mount Sinai Health System describes where advances in locoregional therapy for early-stage hepatocellular carcinoma fit into the therapeutic landscape.
EP. 5: Advances in Locoregional Therapy for Early Stage HCC By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD University of Arizona’s Rachna Shroff, MD, describes the role of systemic therapy with locoregional treatment for early stage hepatocellular carcinoma and highlights treatment strategies of interest that remain under investigation.
EP. 6: Neoadjuvant Therapy to Downstage HCC By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD Reactions to treatment gaps in the neoadjuvant space for hepatocellular carcinoma and implications for incorporating data supporting newer, novel systemic therapies for appropriate patients.
EP. 7: Hepatic Arterial Infusion Chemotherapy for HCC By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD Reactions to recent clinical abstracts that support the use of hepatic arterial infusions for chemotherapy delivery in hepatocellular carcinoma.
EP. 8: Adjuvant Treatment Advances in Operable HCC By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD Perspectives regarding treatment advances using adjuvant approaches that include immunotherapy to treat early-stage hepatocellular carcinoma.
EP. 9: Scoring/Classifying Patients With Advanced HCC By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD Best practices using available scoring systems to evaluate and treat patients with advanced hepatocellular carcinoma.
EP. 10: Systemic Treatment Advances for Advanced HCC By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD Exciting developments using novel therapies as systemic treatment for advanced hepatocellular carcinoma.
EP. 11: Frontline IO for Advanced HCC By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.
EP. 12: Selecting First-Line Therapy for Advanced HCC By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.
EP. 13: The LEGACY Study in HCC By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.
EP. 14: HCC: IO in Liver Transplant Recipients By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.
EP. 15: The COSMIC-312 Study in Advanced HCC By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.
EP. 16: Second-Line Treatment Approaches for Advanced HCC By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.
EP. 17: Biomarkers to Guide HCC Treatment Decisions By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.
EP. 18: Optimizing Precision Medicine in HCC By Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic, Edward Kim, MD, Mount Sinai Medical Center, Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center, Amit Singal, MD, UT Southwestern Medical Center, Rachna Shroff, MD, University of Arizona, Arndt Vogel, MD, Hannover Medical School, Mark Yarchoan, MD Takeaways from a discussion on treatment advances in hepatocellular carcinoma.
